A retrospective, cohort study analyzing efficacy of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas
Latest Information Update: 19 Apr 2022
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 19 Apr 2022 New trial record